Premium
New Huprine Derivatives Functionalized at Position 9 as Highly Potent Acetylcholinesterase Inhibitors
Author(s) -
Ronco Cyril,
Foucault Richard,
Gillon Emilie,
Bohn Pierre,
Nachon Florian,
Jean Ludovic,
Renard PierreYves
Publication year - 2011
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201000523
Subject(s) - acetylcholinesterase , butyrylcholinesterase , chemistry , substituent , aché , stereochemistry , steric effects , active site , selectivity , docking (animal) , in vivo , enzyme , potency , in vitro , biochemistry , medicine , nursing , microbiology and biotechnology , biology , catalysis
Abstract A series of 24 huprine derivatives diversely functionalized at position 9 have been synthesized and evaluated for their inhibitory activity against human recombinant acetylcholinesterase (AChE). These derivatives were prepared in one to five steps from huprine 1 bearing an ester function at position 9. Ten analogues ( 1 , 2 , 6 – 9 , 13 – 15 , and 23 ) are active in the low nanomolar range (IC 50 <5 n M ), very close to the parent compound huprine X. Compounds 2 , 6 , and 7 show a very good selectivity for AChE, with AChE inhibitory activities 700–1160‐fold higher than those for butyrylcholinesterase (BChE). The inhibitory potency of these compounds decreases with the steric bulk of the substituents at position 9. According to docking simulations, small substituents fit into the acyl‐binding pocket, whereas the larger ones stick out of the active site gorge of AChE. Determination of the kinetic parameters of three of the most potent huprines ( 2 , 6 , and 7 ) showed that most of the difference in K D is accounted by a decrease in k on , which is correlated to the increase of the substituent size. A first in vivo evaluation has been performed in mice for the most active compound 2 (IC 50 =1.1 n M ) and showed a rather weak toxicity (LD 50 =40 mg kg −1 ) and an ability to cross the blood–brain barrier with doses above 15 mg kg −1 .